Embattled Chinese vaccine maker Changsheng Bio-technology risks delisting as big shareholders are barred from selling shares

Having lost half its market value in the space of seven days after regulators found it had fabricated data for its rabies vaccines, Chinese pharmaceuticals maker Changsheng Bio-technology now faces a further trauma: possible delisting.
Shares of Changsheng slumped by the 10 per cent daily limit for a seventh consecutive day to 11.75 yuan at the close on Tuesday, erasing 12.5 billion yuan (US$1.83 billion) in market value.
The company was also found to have sold an unqualified vaccine for the treatment of coughs and colds in infants. The medicine failed a test conducted by the state drug administration.
Trading in the company’s stock will be suspended on Wednesday, and when it restarts on Thursday the company will be categorised as a “special treatment” stock because the company does not expect normal business operations to resume in three months, Changsheng said in an exchange statement after the market closed on Tuesday.